CMS Extends Medicares Short-Term Bridge Program for GLP-1 Obesity Drug Coverage The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on January 1, 2027
The participants were divided into five treatment groups: bofanglutide 12 mg (biweekly) bofanglutide 18 mg (biweekly) bofanglutide 24mg (biweekly) bofanglutide 24mg (once weekly) semaglutide 1mg (once weekly) The primary measurement the researchers focused on was HbA1c levels from the baseline to the 24-week follow-up
SPPS uses large quantities of organic solvents often five washes per step, which drives up the waste and environmental footprint for making peptides
Wegovy: It is a once-week injectable medication containing semaglutide
Choose tirzepatide if you want maximum weight loss potential, tried semaglutide and plateaued, or can manage the higher cost
References Mayo Clinic, www.mayoclinic.org NovoNordisk, www.talkGLP-1.com